Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | HCK | P08631 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.44 |
| ▸ | PRKDC | P78527 | 3/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026025 | 0.89 | ESR1 (0.66) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4029788 | 0.89 | ESR1 (0.69) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4027041 | 0.88 | ESR1 (0.60) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4028981 | 0.86 | ESR1 (0.62) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4029602 | 0.85 | ESR1 (0.61) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4026609 | 0.84 | ESR1 (0.69) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4027805 | 0.83 | ESR1 (0.61) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4026423 | 0.81 | ESR1 (0.65) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4026488 | 0.81 | ESR1 (0.70) | ESR1PIK3CDPIK3CBPIK3CGABL1 | |
| SCHEMBL4026000 | 0.81 | ESR1 (0.73) | ESR1PIK3CDPIK3CBPIK3CGABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | claimed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | claimed |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2006-05-25 | — | — | US | claimed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | claimed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | claimed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885PIK3CD 2619/4885PIK3CB 3305/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | ESR1 2487/4885PIK3CD 2207/4885PIK3CB 2823/4885 |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | IKBKB, NFKBIA, IKBKG | ESR1 19/4885PIK3CD 3593/4885PIK3CB 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.